InvestSource Inc.: The Outer Post Increases Web Traffic with Wild Word Chase Contest

Thu. July 03, 2008; Posted: 04:03 AM

July 1, 2008 - Cody Ventures Corporation's (CVCP) (Pink Sheets: CVCP) web property, TheOuterPost.Com announced today the winner of its Wild Word Chase contest. The Wild Word Chase was a week-long contest that prompted community users to follow clues in search of hidden words on the website. The ultimate goal was to create the sentence, "Dryhump rewards those who promote their minds." During the week of the Wild Word Chase Contest, The Outer Post saw an increase of 37% more hits to the website than in the previous week. The contest also increased the number of average page views per user by 120%, as users had to search the entire website looking for clues. This helped Cody Ventures and The Outer Post to close out the month of June with the highest advertising revenue to date. The winner of the contest was announced on TheOuterPost.Com, and will be receiving a prize of an MP3 digital watch. Cody Ventures Corporation president, Roy Cooper stated, "The Wild Word Chase created a lot of user excitement on The Outer Post, which is so important in an industry where consumers must be constantly engaged to stay interested." Roy went on to state, "So far The Outer Post has had contents that encouraged the users to network with each other or invite new friends to the site. We decided to do The Wild Word Chase as a way to introduce our members to more pages of the website and to take them to places on the site they may not have visited before, like the FAQs and the Events page. We figure that this will work to increase our page views not only for this week, but for many more weeks to come as users sign-on to revisit these pages." The Outer Post will be launching its next contest the second week of July.

July 2, 2008 -- Monolithic Power Systems (NASDAQ: MPWR), a leading fabless manufacturer of high-performance analog and mixed-signal semiconductors, announced that the United States District Court for the District of Delaware issued judgment as a matter of law that MPS did not breach its October 1, 2005 Settlement and License Agreement with Linear Technology Corporation (Linear). MPS plans to seek recovery of substantial attorney fees and costs from Linear, pursuant to a prevailing party attorneys fees provision in the Settlement and License Agreement. The court also found as a matter of law that MPS had not willfully infringed the patent claims of U.S. Patent Numbers 5,481,178 and 6,580,258 asserted by Linear against the accused MP1543 product. MPS had discontinued the sales of that product more than 18 months earlier. The court further found as a matter of law that MPS had not indirectly infringed Linear's asserted patent claims and that Linear had failed to introduce any evidence of infringement by any MPS customer. However, the jury returned a verdict that an evaluation board containing the previously discontinued MP1543 product had directly infringed the asserted patent claims and that Linear's patents mentioned above are valid. The parties had stipulated to a total of ten dollars in nominal patent infringement damages in the event that Linear prevailed in that dispute.

July 2, 2008 -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST | Quote | Chart | News | PowerRating) announced that it has signed an exclusive agreement with AstraZeneca to promote and provide other support in the United States for MERREM I.V. (meropenem for injection), an established broad spectrum (carbapenem class) I.V. antibiotic. Cubist will promote and support MERREM I.V. using its existing U.S. acute care sales and medical affairs organizations. AstraZeneca will continue to provide marketing and commercial support for MERREM I.V. The agreement, effective July 1, 2008, establishes a baseline of $20 million annual revenue to Cubist that will be adjusted based on actual MERREM I.V. sales. Other terms of the agreement, including the performance incentives, are confidential. Cubist Executive Vice President and Chief Operating Officer Robert J. Perez said of the agreement: "As a broad spectrum antibiotic, MERREM I.V. is an excellent fit with our Gram positive therapy, CUBICIN, which has experienced the most successful I.V. antibiotic launch in U.S. history in dollar terms. The agreement with AstraZeneca immediately leverages the Cubist sales and medical affairs teams that have contributed to making CUBICIN so successful in the U.S." According to Marion McCourt, Vice-President, GI & Infection, AstraZeneca, "This agreement will allow AstraZeneca to maximize the value of MERREM I.V. while continuing to bring this important product to health care providers and patients. The Cubist sales force is well recognized by infectious disease specialists and is highly respected by its customers."

July 2, 2008 -- PATTERSON-UTI ENERGY, INC. (NASDAQ: PTEN | Quote | Chart | News | PowerRating) reported that for the month of June 2008, the Company had an average of 253 drilling rigs operating, including 248 rigs in the U.S. and 5 rigs in Canada. For the three months ended June 2008, the Company had an average of 245 drilling rigs operating, including 243 rigs in the U.S. and 2 rigs in Canada. Average drilling rigs operating reported in the Company's monthly announcements represent the average number of the Company's drilling rigs that were moving or operating under a drilling contract. The Company cautioned that numerous factors in addition to average drilling rigs operating can impact the Company's operating results and that a particular trend in the number of drilling rigs operating may or may not indicate a trend in or be indicative of the Company's financial performance. The Company intends to continue providing monthly updates on drilling rigs operating shortly after the end of each month.

July 2, 2008 -- Walgreens (NYSE: WAG | Quote | Chart | News | PowerRating) had June sales of $4,810,100,000, an increase of 9.9 percent from $4,378,540,000 for the same month in 2007. Sales in comparable stores (those open at least a year) rose 3.4 percent, while comparable store front-end sales increased 3.5 percent. June front-end sales were helped in part by strong sales of promotional products, consumables and gift cards. Zyrtec, which recently switched from prescription to over-the-counter status, benefited front-end sales by 0.5 percentage points. Meanwhile, front-end sales were hurt by comparisons to last year's introduction in June of alli, the over-the-counter diet medication, and promotional pricing in the photofinishing department. June pharmacy sales increased 9.7 percent, while comparable pharmacy sales increased 3.3 percent. Comparable pharmacy sales were negatively impacted by 2.1 percentage points due to generic drug introductions in the last 12 months. Total prescriptions filled at comparable stores increased 0.8 percent. June prescriptions filled were negatively impacted by 0.6 percentage points due to the switch of Zyrtec to over-the-counter status. There was no impact on comparable prescriptions filled in the month due to calendar day shifts.

Wall Street resumed its sell-off Wednesday after oil hit a new record and a bearish analyst report renewed concerns that General Motors Corp. could run out of cash. The stock market's pullback, which accelerated in the final hours of the week's last full trading day, left the Dow Jones industrial average officially in bear market territory, with the blue chips having fallen more than 20 percent from their October highs. Oil surged to new records above $144 a barrel as the government reported a bigger-than-expected drop in U.S. supplies and as investors worried about tensions in the Middle East. Worries that GM could go so far as to declare bankruptcy only added to investors' unease. The stock fell $1.77, or 15 percent, to $9.98 -- the first close below $10 since September 1954 when Dwight Eisenhower was president. Investors shrugged off better-than-expected sales figures from June and fretted about the company's cash needs. According to preliminary calculations, the Dow fell 166.75, or 1.46 percent, to 11,215.51, the lowest close since August 2006. Broader stock indicators also posted big losses after showing gains for much of the morning. The Standard & Poor's 500 index fell 23.39, or 1.82 percent, to 1,261.52, and the technology-laden Nasdaq composite index fell 53.51, or 2.32 percent, to 2,251.46. The S&P is just shy of the 20 percent pullback that signals a bear market. While the Nasdaq is also in bear market territory, it hit that mark in March, moved higher and has now returned to a bear level. Bond prices rose as investors exited stocks. The yield on the benchmark 10-year Treasury note, which moves opposite its price, fell to 3.97 percent from 4.01 percent late Tuesday. The dollar slipped versus other major currencies, while gold prices fell. Gasoline prices hit a fresh high ahead of the July 4th holiday weekend, increasing half a penny overnight to $4.092 a gallon on average, according to AAA, the Oil Price Information Service and Wright Express. Higher energy prices have caused consumers to pare their spending. Crude oil hit a record $144.32 a barrel in after-hours trading after reaching a record settlement of $143.57, up $2.60 on the New York Mercantile Exchange. The Energy Department reported Wednesday that U.S. crude oil supplies fell more than expected last week. Businesses are also struggling with elevated energy costs, and demand is weakening for autos, heavy machinery and steel. The Commerce Department said Wednesday that factory orders rose by 0.6 percent in May. The result was in line with a consensus of Wall Street economists surveyed by Thomson Financial, but was much smaller than the gain of 1.3 percent for April.

ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway, GO TO: www.investsourceinc.com.

To hear "The Fastest 60 Seconds in the Small-Cap Market," please go to www.ceo-corner.com This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation to buy or sell securities. InvestSource, Inc. has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by InvestSource, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this release have not given an opinion or approved the statements made in this release.

InvestSource, Inc. is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. InvestSource, Inc. affiliates, officers, directors and employees may also have bought, or may buy the shares discussed in this opinion and may profit in the event of a rise in value. InvestSource, Inc. will not advise as to when it decides to sell and does not, and will not, offer any opinion as to when others should buy or sell; each investor must make that decision based on his or her judgment of the market. Please consult your broker before purchasing or selling any securities mentioned herein. InvestSource has agreed to be compensated 50,000 shares of unrestricted stock of CVCP for services rendered. To view full disclaimers, please go to http://investsourceinc.com/php/disclaimer.php (disclaimers).

CONTACT: InvestSource, Inc WWW: http://www.investsourceinc.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for CVIC click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index